Varenicline Tartrate
(var en’ ah klin)
Chantix
PREGNANCY CATEGORY C
Drug Classes
Nicotine receptor agonist
Smoking deterrent
Therapeutic Actions
Selectively binds with specific neuronal nicotinic acetylcholine receptors; acts as an agonist at these sites while preventing nicotine binding to these receptors. This mechanism is thought to aid in smoking cessation.
Indications
Aid to smoking cessation treatment
Contraindications and Cautions
Contraindicated with hypersensitivity to any component of the drug, lactation.
Use cautiously with pregnancy, history of CV disease.
Available Forms
Capsules—0.5, 1 mg
Dosages
Adults
Patient should pick a date to stop smoking and begin drug therapy 1 wk before that date; or patient can begin drug and quit smoking between days 8 and 35 of treatment.
Days 1–3, 0.5 mg/day PO; days 4–7, 0.5 mg PO bid; day 8 until the end of treatment, 1 mg PO bid. Drug should be taken after eating with a full glass of water. Treatment should last 12 wk; patients who successfully quit smoking in that time may benefit from another 12 wk to increase the likelihood of long-term abstinence. Patients who fail to quit smoking during the 12 wk or who relapse after treatment can be treated again when factors leading to failed attempt have been identified and addressed.
Pediatric patients
Safety not established for children younger than 18 yr.
Patients with severe renal impairment
Initially, 0.5 mg/day PO; titrate to 0.5 mg PO bid. If on dialysis, 0.5 mg/day.
Pharmacokinetics
|